{"name":"Evommune, Inc.","slug":"evommune-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EVO301","genericName":"EVO301","slug":"evo301","indication":"Relapsed or refractory B-cell acute lymphoblastic leukemia","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EVO101","genericName":"EVO101","slug":"evo101","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"EVO301","genericName":"EVO301","slug":"evo301","phase":"phase_2","mechanism":"EVO301 is a monoclonal antibody targeting CD22.","indications":["Relapsed or refractory B-cell acute lymphoblastic leukemia"],"catalyst":""},{"name":"EVO101","genericName":"EVO101","slug":"evo101","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOODk1UWVyNkp2ZURVbGZXOUVlZlZTcnpkdGoybHNSaFB1VGlZbXlhMXV2N0RxT3lKTk12dW5tUTRUcXJuZmtxLVd1ZG9lU3pCcHhlcTJ4UHdVc3Z0ZERBVW9PdmFReVZOZmt2Yy1fMFdrTEhLZ2RuN2ZnTWxPOTlOOFNDcWtNMnA5TDNEanVibHRkdzg?oc=5","date":"2026-04-07","type":"pipeline","source":"Pharma Voice","summary":"Evommune bucked biotech IPO drought and is focused on the long game - Pharma Voice","headline":"Evommune bucked biotech IPO drought and is focused on the long game","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPSXp3eGU1SlBPejZYWURTRFdNUFVKTE1Oc1J0TUdCOER3ZnduUFNtamtOSlNXS0Z0MVlhaU9paEZJVnZhbjJJeS1NUkk4VXdDZ0Y3ZlZIZTVtclYwMEdVNlJNS05sODE2Z09HY2JWc2JOSTNJNk9vRVQ2Rm5aaEVYd3pSTF83dWpQZlVNMGJLd2pfa1BSWUZFTGxHZVdUWmRt?oc=5","date":"2026-03-26","type":"pipeline","source":"BioWorld News","summary":"Corvus leads drug developers as index climbs in early 2026 - BioWorld News","headline":"Corvus leads drug developers as index climbs in early 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNVWZ4Yzl2ZlVxeEZqNWMwSzhpTU9BbTh3aV85ZXFXQUxSbFpJdzBmTWVjd3k2QjhKLXYzcXdjRGFpZUhzYTJBcE1vRFNRcGh0eEczZGROV21NSHcxRGwxYXg4SlNucFlsWWlETEx0NVNnVGpreWdmOVBPRXIyUS1vSnVtRmlBdVEyOUVyaG9DdmNEencxd3o0QQ?oc=5","date":"2026-02-11","type":"regulatory","source":"Mugglehead Magazine","summary":"Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Magazine","headline":"Biopharma companies Evommune and Nektar soar on eczema treatment data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPb3pfOTZBUUhYd0FYS1JJam0wRWI2Q3BFc2ptVjFzUnY2bFQ1akY3UDY5aFJwTjZlQl83amhjUjZOVElkV0RzS2Q1QVNZV3Y0VS12X1ltNUlIUE9zZUlJdnVCaFJvbmpOZ0RRUGlRS0FpYkdMX1FYNVl5c2NuRy0zX1V1eER2Y2MtY0p3ek11VlpLbklabVhRc2U2NzZnVkVLRUp3eEVLS3pqbWRKMURqSTBRUEZhaldzT3JOdGRURjRiUQ?oc=5","date":"2025-12-19","type":"pipeline","source":"reuters.com","summary":"Aktis Oncology files for US IPO as biotech listings rebound - reuters.com","headline":"Aktis Oncology files for US IPO as biotech listings rebound","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxQdTlxTGg1bFVlN3BkcWFuNDI1R19RRENYRWJEYnFSTWozOEFZS3hLc09hRHl0bGkxQXd2akM3MTMzd2NfTnlnTzBveXFybWkwQ1VROVlmUFdHWWRHMFZGWDc0VlBfemJueVcyTFR3RDEyaDFWMV80WkpUX3pHMnRCSGM0a0lJcFNsRzEyQUl6SW9pZVBQaXFqSE9nZEZSaFhSUGJ6Ymt4aTV5NWlERzNDU1BMVjJBM2hFNklOcFZyazNkTWdMQk0zakhxQWh6VkN0VXp1Y0NmeVJtcWRNb0hycE81X0toc1RpRjkyMGJhWVRfLXlCT1VUMTZHS3RkdmJodndNYVF4QTlIcnZKSWxIRHhNZVVQVzYz?oc=5","date":"2025-12-19","type":"earnings","source":"Benzinga","summary":"Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stock - Benzinga","headline":"Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stock","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"globenewswire.com","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - globenewswire.com","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPZHpIR0dxbmp4RTMzeURBS09QLTFKN2JDRG5PbF9JVVJZRHYzUjdWZ29mYWJSOE1nbnowZmNIQklhLWxObERzUUlFQmxMdUE4TWFaT05DTk5OS3F3XzNxQnBOU3VMLWtqVHlsbWZLQ2NwNFBOZTNiRkZDcFVIZEZ2YWZFRUQ4ZUZwREJhR1FlQ0MzOGdnTldNZUdCUUs4VUds?oc=5","date":"2025-11-05","type":"pipeline","source":"BioPharma Dive","summary":"Evommune nabs $150M in IPO amid federal shutdown - BioPharma Dive","headline":"Evommune nabs $150M in IPO amid federal shutdown","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9xRXUzYUpHdVNSb0NQYXpSdW85alhjeTRERjNod3l1cnRGTHdYVHQyREg5eWl4OEhqdG9wMmZaRXg4NHZaZElhSEJ4UFZ5U29lNmFxUC1lTXdtUQ?oc=5","date":"2025-11-05","type":"pipeline","source":"TradingView","summary":"EVMN Stock Price and Chart — NYSE:EVMN - TradingView","headline":"EVMN Stock Price and Chart — NYSE:EVMN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9WUEFVZlBqOEt5RUlhWm9ia0E1ampDcWpVa3ZZdGY4V2pVME10akJlRThZSE9vV011bnZwVWZTU1hpR1pCUTJHNWxlT0tra0VTYlJr?oc=5","date":"2025-10-31","type":"pipeline","source":"Stock Titan","summary":"EVMN Stock Price, News & Analysis - Stock Titan","headline":"EVMN Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQd1pWcVRjNjFGYzRIMTlkMmctOGRPcVV4dFVXWWZ3amxmZG1aRC1OTG00ZmlYeG1yMnlIaExweXdoN3JLNDFRYzl4ckQ1WjYtWURTdGJZWlpySXFyUFB1aEd6Ti1Ea25TVDJpOU9Yd2xSMlZXY0xtLUdyTUVzbnp6NThWMnJ2d21SSVB3S3JuU0MwZkpNdjdVNg?oc=5","date":"2025-10-14","type":"pipeline","source":"Seeking Alpha","summary":"Evommune Aims For IPO In Bifurcated Biopharma Market (Pending: EVMN) - Seeking Alpha","headline":"Evommune Aims For IPO In Bifurcated Biopharma Market (Pending: EVMN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPV1BSUnp6M3cyb3A2Sk1kc1I4clBEVEd3aE1lbTV5Y0xreWJTc1k0U2hWMmpwTlczMkRudk5JcHFac0xsa3hwSjBPS2J6SFdDTHYxbTFmNkVPRHNsdnNZOE01VkZxNm04ZzAzNXVfcmtqUGVyM2hfaXFIMWl6X1lKcWkzaWhxWWlhblFaMlBNNVpHVDRUNERPRUxtMHgzNFg5Slg2SkYwQWVLUHpwcXhJbw?oc=5","date":"2025-10-10","type":"pipeline","source":"BioPharma Dive","summary":"Evommune files for IPO to advance immune drug work - BioPharma Dive","headline":"Evommune files for IPO to advance immune drug work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTndjRmdiY2YxalptdWE0V2tvLXFjWUo5WmxjTzU2VmJwVldlQ2hBTjdVWU9ZalFtM3F5VGVmVGg2M2NGZ1ZhQVNobUMzOWNRZVpTR3V3U2QwVVltQlF0Mk1DQ0ZpUmRaeHNFV3h4QXFPZ19mQ0tZY3JjYk5NVmtCLXdPcWNnUTV3Vk5QVGVkbFMtdkV3R1FmTUtKQU1oRVRHSmZJNmhkeVRZdw?oc=5","date":"2025-10-09","type":"pipeline","source":"The Business Journals","summary":"Peninsula biotech Evommune puts skin in IPO game - The Business Journals","headline":"Peninsula biotech Evommune puts skin in IPO game","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}